

Tako-Tsubo (Stress) Cardiomyopathy: Pathophysiology and Natural History.

By

Christopher James Alan Neil

Professor John Horowitz, Advisor

A Thesis Submitted In Fulfillment Of The Requirements
For The Degree Of Doctor of Philosophy

Faculty of Health Science
School of Medicine
The University of Adelaide

December 2012

Abstract

Introduction. Tako-Tsubo cardiomyopathy (TTC), also known as apical ballooning syndrome, is a recently described form of acute cardiac dysfunction of uncertain pathogenesis, which occurs with greatest frequency among post-menopausal women. Presentation generally mimics that of an acute myocardial infarction (AMI) but is independent of the presence of fixed coronary artery disease and is classically preceded by severe stress. While patients with TTC with ST elevation are typically diagnosed at emergent cardiac catheterization, the majority does not exhibit initial ST elevation. It is not known whether TTC can be reliably distinguished from AMI non-invasively on the basis of clinical and laboratory tests. Although there is considerable uncertainty about the pathogenesis of TTC, pronounced catecholamine release and an acute inflammatory process are implicated. Systolic dysfunction most commonly affects the apex of the left ventricle and has generally been considered self-limiting and fully reversible. Although obvious hypokinesia resolves and left ventricular ejection fraction tends to return to normal, data that challenge this view include abnormal elevation of natriuretic peptide concentrations, 3 months from the index event, together with the late persistence of some inflammatory cells on LV biopsy.

Methods. In three experimental chapters, this thesis examines aspects of (a) diagnosis (b) pathogenesis and (c) recovery, in a cohort of 125 TTC patients (mean age 67 years; 95% female). As regards diagnosis, it was hypothesized that an arbitrarily derived 'TTC score', incorporating NT-proBNP levels, might facilitate early differentiation from a cohort of females with AMI (n = 56; mean age 70 years). The primary comparison was based on data available at 24 hours post-admission. In a subset of 49 TTC patients, acute multisequential

cardiac magnetic resonance imaging was performed and repeated at 3 months. Pathogenetic investigations:- Extent of oedema was quantified both regionally and globally from T₂ weighted images, with comparison to data from 10 age-matched female controls. Correlations were sought between oedema and the extent of hypokinesia, catecholamine release, N-terminal proBNP release and markers of systemic inflammatory activation. Functional recovery was assessed via 2D speckle-tracking echocardiography (n = 36) and 15 patients, ≥1 year from their index TTC admission, underwent T₁ mapping via CMR in order to address the question of whether residual fibrosis is present after TTC.

Results.

A. Diagnosis: TTC scores were significantly different (TTC group median was 4, vs. 2 in the ACS group; P < 0.0001). Receiver operator curve analysis demonstrated an area under the curve (AUC) of 0.74 (P < 0.0001), with 62% sensitivity and 75% specificity for a score ≥4; when stressor exposure was scored in both groups, AUC was 0.89 (P<0.0001), with 78% sensitivity and 82% specificity (TTC score ≥4). The TTC score separated groups when haemodynamic compromise was absent (AUC 0.80, P<0.0001), but not when hypotension or heart failure were evident (P = NS).

B. Pathogenesis: In the acute phase of TTC, T₂-weighted signal intensity was greater at the apex than at the base (P < 0.0001) but was nevertheless significantly elevated at the base (P < 0.0001), relative to control values; over three months, T₂-weighted signal decreased substantially but remained abnormally elevated (P = 0.02). Regional extent of edema correlated inversely with radial myocardial strain. There were also direct correlations between global T₂-weighted signal and plasma normetanephrine (r=0.33, p=0.028), peak NT-proBNP (r=0.40, p=0.0045), C-reactive protein (r=0.34, p=0.023) and troponin T release (r=0.29, p=0.045).

C. Recovery: Patients exhibited lower global longitudinal strain than controls [mean 17.9 ± 3.1 (SD)%, versus 20.3 ± 1.6; P = 0.0057], but did not differ significantly from controls in values of apical twist. Three month global longitudinal strain correlated with the extent of residual NT-pro-BNP elevation (r=0.38, P=0.027), but did not correlate with markers of the acute severity of the TTC attack. Finally, patients with a remote history of TTC,

demonstrated significant intramyocardial fibrosis ($V_e = 0.24$), versus controls ($V_e = 0.21$, $P = 0.013$), but extent of which was not correlated with global longitudinal strain.

Conclusions. (1) The TTC score, while not of itself diagnostic, may facilitate the differentiation of TTC in patients with presumed ACS, but with diminished efficacy in the presence of haemodynamic compromise. (2) TTC is associated with slowly resolving global myocardial edema, the acute extent of which is correlated with regional contractile disturbance and acute release of both catecholamines and NT-proBNP. (3) Imaging data after TTC indicate that, at 3 months, recovery is substantial, but not complete; at ≥ 1 year there is evidence of diffuse interstitial myocardial fibrosis. Further efforts to expedite diagnosis, delineate pathogenesis and evaluate residual disability may assist in the development of appropriate treatment regimens.

Declaration

This thesis is the result of my own investigation, except where otherwise stated. It contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Signed:

.....

Christopher J. A. Neil, 17th December 2012

Acknowledgements

I am truly indebted and thankful to Professor John Horowitz for his help in generating ideas, support and guidance throughout. I would also like to acknowledge A/Prof Christopher Zeitz, who, as well as co-supervising this project, took a leading role among cardiologists at The Queen Elizabeth and Lyell McEwen Hospitals in recruiting patients for this study.

My colleagues, Dr Thanh Ha Nguyen, Dr Yuliy Chirkov, Ms Jeanette Stansborough and Ms Angela Kucia have all been of great assistance in the TTC project, with both intellectual contributions as well as involvement in the day-to-day work of the study.

This thesis relied heavily on cardiac imaging personnel: in this regard, notable thanks goes to Ms Sue Collings, Mr David Lockyer, Ms Kerry Williams, Ms Tharshy Pasupathy, Mr Matthew Chapman, Mr Brett Stocker, Dr Betty Raman, Dr Devan Mahadevan, Professor John Beltrame and Dr Ewan Choo.

I would like to thank the National Health and Medical Research Council and for funding this work and, similarly, the generosity of numerous patients and controls in giving their time for the studies described herein.

Finally, I would like to thank my wife, Sally, and children, Ella, Jonah, Daisy and Shiloah, for their support, patience and understanding.

Statement of contribution to research

The studies were conceived and designed jointly by Professor Horowitz and myself.

Execution

I performed all the recruitment and organization of patients into the studies, with the assistance of Ms Jeanette Stansborough (research nurse). I collected all clinical data, also with assistance from Ms Stansborough. I performed echocardiographic studies and cardiac magnetic resonance scans at The Queen Elizabeth Hospital. Dr Yuliy Chirkov performed the platelet aggregometry studies. Metanephrine assays were performed by Dr Malcolm Whiting at SA Pathology, Adelaide. Collagen biomarker assays was performed by Dr Michael Metz at ClinPath, Adelaide.

Analysis

All data were collated and analyzed by myself. Inter-observer analyses were performed with Dr Thanh Ha Nguyen, Mr Matthew Chapman and Ms Tharshy Pasupathy.

List of published studies

This thesis is based in part on the following original studies, which exist in published form:

1. Nguyen TH, Neil CJ, Sverdlov AL, et al. N-terminal pro-brain natriuretic protein levels in takotsubo cardiomyopathy. *The American Journal of Cardiology* 2011, 108, 1316-1321.
2. Neil CJ, Nguyen TH, Sverdlov AL, et al. Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history. *Expert Rev Cardiovasc Ther* 2012, 10, 215-221.
3. Neil CJ, Nguyen TH, Kucia A, et al. Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T₂-weighted cardiac MRI. *Heart* 2012, 98, 1278-1284.
4. Neil CJ, Chong CR, Nguyen TH, Horowitz JD: Occurrence of Tako-Tsubo cardiomyopathy in association with ingestion of serotonin/noradrenaline reuptake inhibitors. *Heart, Lung & Circulation* 2012, 21, 203-205.

Table of Contents

Abstract	2
Declaration	5
Acknowledgements	6
Statement of contribution to research	7
List of published studies	8
List of Tables	15
List of Figures	16
List of abbreviations used	17
Chapter 1: Literature review	18
1.1 Acute myocardial injury: ischaemic and non-ischaemic causes	19
1.2 Tako-Tsubo cardiomyopathy as a non-ischaemic acute cardiac injury	20
1.2.1 Historical aspects	22
1.2.2 Differentiation from myocardial infarction: early studies	23
1.2.3 Evolution of definition	23
1.2.3.1 The problem of ‘mandatory’ cardiac catheterization	24
1.2.3.2 Is exclusion of fixed coronary disease enough?.....	25
1.2.3.3 Can TTC coexist with CAD, phaeochromocytoma or myocarditis?	25

1.2.3.4	Excluding an ischaemic basis for regional contractile dysfunction in TTC	27
1.3	Tako-Tsubo cardiomyopathy: clinical aspects	28
1.3.1	Epidemiology	28
1.3.2	Acute presentation	29
1.3.2.1	Gender disparity	29
1.3.2.2	Age and cardiometabolic risk profile	30
1.3.2.3	Antecedent psychological and physiological stress in TTC	31
1.3.2.4	TTC complicating medical/surgical illness.....	31
1.4	Associated abnormalities	34
1.4.1	ECG changes and arrhythmogenicity	34
1.4.1.1	ST-T wave abnormalities: specificity for TTC	34
1.4.1.2	QT prolongation and torsade de pointes.....	34
1.4.2	Laboratory findings.....	36
1.4.2.1	Markers of myocardial necrosis.....	36
1.4.2.2	Natriuretic peptide elevation.....	36
1.4.2.3	Elevation of catecholamine levels	38
1.4.3	Echocardiography.....	42
1.4.3.1	Doppler echocardiography	43
1.4.3.2	Diastolic function	44
1.4.3.3	Advanced echocardiography/myocardial mechanics	45
1.4.4	Cardiovascular magnetic resonance imaging.....	48
1.4.4.1	Evaluation of myocardial necrosis or scar	48
1.4.4.2	Oedema imaging.....	49
1.4.5	Nuclear imaging findings	50
1.4.5.1	Nuclear perfusion imaging.....	50
1.4.5.2	Cardiac sympathetic neuroimaging	51
1.4.5.3	“Metabolic” imaging findings	51
1.5	Pathogenesis.....	52
1.5.1	Anatomical and histological descriptors	52
1.5.1.1	Anatomical problems.....	52
1.5.1.2	Evidence from histology and ultrastructural analysis.....	56
1.5.2	Is there a problem with myocardial perfusion?	56
1.5.2.1	Diffuse or multivessel epicardial coronary spasm	57
1.5.2.2	Coronary reserve and microvascular dysfunction	57
1.5.3	Biochemical bases of hypokinesia: calcium, energetics and <i>stunning</i>	59
1.5.4	Does catecholamine exposure “cause” TTC?.....	61
1.5.4.1	“Non-classical” actions of catecholamines: oxidative stress	62

1.5.5	Other potential biochemical effectors	64
1.5.5.1	Neuropeptide Y	64
1.5.5.2	Nitric oxide	64
1.5.5.3	Potential proadrenergic effect of BNP	65
1.5.6	Factors engendering rapid recovery: biochemical determinants.....	66
1.5.7	Relevance of postulated animal models.....	67
1.5.7.1	Observations from rodent models of catecholamine cardiotoxicity.....	67
1.5.7.2	Application to TTC: rodent models.....	68
1.5.7.3	A non-human primate model of TTC.....	73
1.5.8	Key unanswered questions.....	73
1.5.8.1	Insights into predisposition in females.....	73
1.5.8.2	What underpins individual susceptibility to TTC?.....	75
1.5.8.3	Basis for acute hemodynamic heterogeneity.....	77
1.5.9	Potential links to other forms of acute cardiomyopathy.....	78
1.6	Natural history of Tako-Tsubo cardiomyopathy.....	81
1.6.1	Short-term complications and outcomes	81
1.6.1.1	Acute complications of TTC	81
1.6.1.2	Haemodynamic status in TTC	82
1.6.2	Long term outcome.....	83
1.7	Therapeutic considerations	84
1.8	Scope of the current studies	85
1.9	Tables	86
1.10	Figures	93
Chapter 2:	Clinical Studies in TTC: Towards Expedited Diagnosis	96
2.1	Background	97
2.1.1	Towards expedited diagnosis: rationale.....	98
2.1.2	Potential components of a diagnostic algorithm: candidates.....	99
2.1.3	A summative “TTC score” for early diagnosis of TTC?.....	102
2.1.4	Development of a ‘TTC score’	102
2.1.5	Aims and Hypotheses	103
2.2	Methodology.....	103
2.2.1	Patient selection: TTC group.....	103
2.2.2	Patient selection: ACS/acute MI	104
2.2.3	Patient management in hospital	104
2.2.4	Investigations.....	105

2.2.4.1	Biochemical data	105
2.2.4.2	Angiographic and invasive haemodynamic assessment	106
2.2.4.3	ECG analysis and definitions	107
2.2.4.4	Clinical imaging	107
2.2.5	Clinical event definitions and long term follow-up	108
2.2.6	Statistical methodology	109
2.3	Results	109
2.3.1	Patient characteristics at admission	109
2.3.2	Clinical outcomes in TTC and ACS	110
2.3.3	Haemodynamic and imaging findings in TTC	111
2.3.4	Long-term follow-up	111
2.3.5	Presenting ECG and biomarker findings in TTC, versus ACS	112
2.3.6	NT-proBNP in TTC versus ACS	113
2.3.6.1	Diagnostic utility of NT-proBNP: effect of haemodynamic status	113
2.3.6.2	Diagnostic utility of NT-proBNP: effect of ST-elevation	114
2.3.7	Effectiveness of TTC score	114
2.3.7.1	Effectiveness of TTC score: effect of haemodynamic status	115
2.3.7.2	Effectiveness of TTC score: effect of ST-elevation	115
2.3.8	Optimization of NT-proBNP thresholds: sensitivity and specificity	115
2.4	Discussion	116
2.4.1	Patient population and clinical status	116
2.4.2	Additional clinical data	117
2.4.3	ECG patterns in TTC versus ACS	118
2.4.4	NT-proBNP elevation in TTC versus TTC	119
2.4.5	The TTC score: potential for expedited diagnosis	120
2.4.6	Limitations	121
2.5	Conclusions and clinical application	123
2.6	Tables	124
2.7	Figures	130

Chapter 3: Inflammatory activation during the acute phase of Tako-Tsubo

	cardiomyopathy: information from cardiac magnetic resonance	135
3.1	Introduction	136
3.2	Methodology	137
3.2.1	Patient selection	137
3.2.2	Clinical protocol	138

3.2.3	Biochemical investigations	138
3.2.4	Platelet responsiveness to nitric oxide	138
3.2.5	Control subject selection	139
3.2.6	Cardiac magnetic resonance imaging	139
3.2.7	T ₂ -weighted signal quantitation methodology	140
3.2.8	Global and regional wall motion quantitation.....	142
3.2.9	Statistics.....	142
3.3	Results	143
3.3.1	Patient/control characteristics	143
3.3.2	CMR findings in TTC: T ₂ -w SI quantification.....	144
3.3.3	Correlates of corrected T ₂ -w values	145
3.4	Discussion	146
3.4.1	Implications of global oedema in TTC.....	146
3.4.2	Implications of persistent/slowly resolving oedema in TTC	148
3.4.3	Implications for pathogenesis: demonstration of catecholamine effect	148
3.4.4	NT-proBNP and troponin elevation in relation to underlying oedema	149
3.4.5	Markers of systemic inflammation in relation to cardiac oedema.....	150
3.4.6	Limitations	150
3.5	Conclusions	151
3.6	Tables	152
3.7	Figures	154
Chapter 4:	Recovery from TTC: short and long-term aspects.	160
4.1	Introduction	161
4.1.1	Evaluation of subtle LV dysfunction and fibrosis: imaging tools	162
4.1.2	Aims and hypotheses.....	163
4.2	Methodology.....	164
4.2.1	Patient/subject selection	164
4.2.2	Echocardiographic methodology (Study 1 and 2).....	165
4.2.2.1	Serial protocol and analysis	165
4.2.2.2	Multidirectional deformation and rotational parameters	166
4.2.2.3	Non-2DS echocardiographic parameters	167
4.2.3	Additional biological investigations (Study 1).....	168
4.2.4	CMR methodology	168
4.2.4.1	Scanning protocol.....	168
4.2.4.2	Derivation of T ₁ and V _e values	170

4.2.4.3	Phantom studies	171
4.2.4.4	Other CMR data analysis	172
4.2.5	Statistics	172
4.3	Results	172
4.3.1	Patient and control characteristics	172
4.3.2	Results of Study 1	173
4.3.2.1	Serial echocardiographic indices and time-course of recovery	173
4.3.2.2	3-month values of nominated 2DS indices, versus controls (Hypothesis 1a).....	173
4.3.2.3	Acute-phase determinants of residual deficit in global longitudinal strain (Hypothesis 1b)	174
4.3.2.4	Determinants of residual deficit in global longitudinal strain (Hypothesis 1c).....	174
4.3.3	Results of Study 2	174
4.3.3.1	Evidence of myocardial fibrosis at ≥ 1 year (Hypothesis 2a)	175
4.3.4	Correlates of extent of myocardial fibrosis at ≥ 1 year (Hypothesis 2b).....	175
4.4	Discussion	175
4.4.1	Non-deformational parameters in acute and recovery phases (Study 1).....	176
4.4.2	Deformational parameters in acute and recovery phases (Study 1)	176
4.4.3	Subtotal LV recovery in TTC and its correlates (Hypotheses 1a, 1b and 1c)....	177
4.4.4	Myocardial fibrosis in TTC and its correlates (Study 2)	178
4.4.5	Post-mortem findings in support of post-TTC myocardial fibrosis	179
4.4.6	Limitations.....	180
4.5	Summary and conclusions.....	182
4.6	Tables and Figures	184
Chapter 5:	Conclusions and future perspectives.....	196
5.1	Summary: major findings	197
5.2	Implications of these findings	198
5.3	Key unresolved issues related to the current thesis	199
5.4	Potential means addressing these unresolved issues.....	201
5.5	Priorities in advancing the understanding of TTC:.....	203
References	206

List of Tables

Table 1.1	Conditions associated with raised cardiac troponins	86
Table 1.2	Mayo Clinic diagnostic criteria for Tako-Tsubo cardiomyopathy	87
Table 1.3	Common or salient stressors/precipitants* of TTC	88
Table 1.4	Major pathogenetic theories in TTC	89
Table 1.5	Important seven-transmembrane-spanning receptors	90
Table 1.6	Histological and ultrastructural findings in patients with acute TTC.....	90
Table 1.7	Case-control studies examining sympathetic responsiveness in TTC.....	91
Table 1.8	Cases of TTC/shock, with rapid improvement on Levosimendan.....	92
Table 1.9	Precipitation of TTC with dobutamine: selected case reports	92
Table 2.1	Comparison of acute clinical and angiographic features.....	124
Table 2.2	Classification of identified antecedent stressors in TTC group.....	125
Table 2.3	Haemodynamic and imaging characteristics of TTC patients.....	126
Table 2.4	Comparison of acute biochemical and ECG features.....	127
Table 2.5	Evolution of selected ECG findings in TTC.....	128
Table 2.6	Contribution of extent of NT-proBNP elevation to potential discrimination between TTC and ACS.....	129
Table 3.1	Patient and control characteristics, Studies 1 and 2.....	152
Table 3.2	CMR findings: LV volumes and functional indices	153
Table 4.1	Phantom manufacture according to specified T1 and T2 times.....	184
Table 4.2	Clinical and laboratory features in patients and controls.....	185
Table 4.3	Non-deformational parameters of LV function	186
Table 4.4	Longitudinal and rotational parameters of LV function	187
Table 4.5	Radial and circumferential deformational indices.....	188
Table 4.6	CMR indices for Study 2	189

List of Figures

Figure 1.1	Selected examples from the cardiac imaging of TTC.....	93
Figure 1.2	Microvascular function in TTC.	94
Figure 1.3	Representative haemodynamic findings in "obstructive TTC"	95
Figure 2.1	Discriminatory value of extent of NT-proBNP elevation in TTC	130
Figure 2.2	Discriminatory value of NT-proBNP in relation to ST-elevation	131
Figure 2.3	Discriminatory value of TTC scores	132
Figure 2.4	Value of TTC scores with respect to haemodynamic status	133
Figure 2.5	Discriminatory value of TTC scores with respect to ST-elevation	134
Figure 3.1	Example T ₂ -weighted short axis images	154
Figure 3.2	T ₂ -w SI data from normal controls and acute TTC patients.....	155
Figure 3.3	Colour-coded bull's-eye plots of T ₂ -w SI in TTC versus controls.....	156
Figure 3.4	Acute and 3 month T ₂ -w SI compared by ANOVA	157
Figure 3.5	Peak radial strain versus corrected T ₂ -w SI, by region.....	158
Figure 3.6	Acute phase correlations between global T ₂ -w SI and plasma normetanephrine, NT-proBNP, troponin T and C-reactive protein.....	159
Figure 4.1	Phantom validation of MOLLI-derived T1 values.....	184
Figure 4.2	Measurement and reproducibility characteristics of main indices.	189
Figure 4.3	Recovery of LV functional indices	190
Figure 4.4	Comparison of LV function 3-month post-TTC, versus controls.....	191
Figure 4.5	Relationship between global longitudinal strain with LV mass.	192
Figure 4.6	Relationship between global longitudinal strain and NT-proBNP concentration at 3 months.....	192
Figure 4.7	Comparison of V _e in TTC patients versus age-matched controls.....	193
Figure 4.8	Selected postmortem histological images	194
Figure 4.9	Further histological depiction of intramyocardial fibrosis.....	195

List of abbreviations used

MI	Myocardial Infarction
STEMI	ST-Elevation Myocardial Infarction
NSTEMI	Non-ST-Elevation Myocardial Infarction
TTC	Tako-Tsubo Cardiomyopathy
ACS	Acute Coronary Syndrome
LV	Left Ventricle
CAD	Coronary Artery Disease
TIA	Transient Ischaemic Attacks
ANP	Atrial Natriuretic Peptide
BNP; NT-proBNP	B-Type Natriuretic Peptide; Amino-Terminal Prohormone Of BNP
ET-1	Endothelin 1
NPR-C	Natriuretic Peptide Receptor C
cGMP	Cyclic Guanosine Monophosphate
AR; β AR	Adrenoceptor; Beta-Adrenoceptor
SR	Sarcoplasmic Reticulum
SERCA	Sarco(Endo)Plasmic Reticulum Calcium ATPase
NET	Norepinephrine Transporter
COMT	Catecholamine O-Methyl Transferase
MAO	Monoamine Oxidase
VMA	Vanillylmandelic Acid
HPLC	High Performance Liquid Chromatography
LVEF	Left Ventricular Ejection Fraction
WMSI	Wall Motion Score Index
PCWP	Pulmonary Capillary Wedge Pressure
LGE	Late Gadolinium Enhancement
CMR; CE-CMR	Cardiovascular Magnetic Resonance; Contrast-Enhanced CMR
SPECT	Single Photon Emission Computed Tomography
SNT	Sympathetic Nerve Terminal
LVOT	Left Ventricular Outflow Tract
LAD	Left Anterior Descending
PDA	Posterior Descending Artery
NOS	Nitric Oxide Synthase
PI3K	Phosphoinositide 3-Kinase
PKB	Protein Kinase B
PARP	Poly-ADP Ribose Polymerase
GRK5	G Protein-Coupled Receptor Kinase 5
LPS	Lipopolysaccharide
TNF- α	Tumour Necrosis Factor Alpha
IL	Interleukin
SPAIR	SPECTral Attenuated Inversion Recovery
SENSE	SENSitivity Encoding
T ₂ -W SI	T ₂ -Weighed Signal Intensity
2DS	2D-speckle tracking
V _e	Extracellular volume